PL3713557T3 - Deuterowane analogi d-seryny i ich zastosowania - Google Patents

Deuterowane analogi d-seryny i ich zastosowania

Info

Publication number
PL3713557T3
PL3713557T3 PL18825828.9T PL18825828T PL3713557T3 PL 3713557 T3 PL3713557 T3 PL 3713557T3 PL 18825828 T PL18825828 T PL 18825828T PL 3713557 T3 PL3713557 T3 PL 3713557T3
Authority
PL
Poland
Prior art keywords
deuterated
applications
analogues
serine
serine analogues
Prior art date
Application number
PL18825828.9T
Other languages
English (en)
Inventor
Dario Doller
Christopher L. Brummel
Julie F. Liu
Roger D. Tung
Original Assignee
Sun Pharmaceutical Industries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries, Inc. filed Critical Sun Pharmaceutical Industries, Inc.
Publication of PL3713557T3 publication Critical patent/PL3713557T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL18825828.9T 2017-11-22 2018-11-21 Deuterowane analogi d-seryny i ich zastosowania PL3713557T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762590109P 2017-11-22 2017-11-22
US201862636081P 2018-02-27 2018-02-27
US201862636427P 2018-02-28 2018-02-28
US201862755157P 2018-11-02 2018-11-02
PCT/US2018/062263 WO2019104179A1 (en) 2017-11-22 2018-11-21 Deuterated analogs of d-serine and uses thereof

Publications (1)

Publication Number Publication Date
PL3713557T3 true PL3713557T3 (pl) 2025-09-22

Family

ID=64755715

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18825828.9T PL3713557T3 (pl) 2017-11-22 2018-11-21 Deuterowane analogi d-seryny i ich zastosowania

Country Status (13)

Country Link
US (4) US20200368193A1 (pl)
EP (2) EP4560024A3 (pl)
JP (3) JP7518765B2 (pl)
KR (1) KR102916897B1 (pl)
CN (1) CN111491629A (pl)
AU (2) AU2018371784B2 (pl)
BR (1) BR112020010156A2 (pl)
CA (1) CA3082834A1 (pl)
IL (2) IL274585B2 (pl)
MX (1) MX2020005336A (pl)
PL (1) PL3713557T3 (pl)
TW (1) TWI886093B (pl)
WO (1) WO2019104179A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018371784B2 (en) 2017-11-22 2024-10-17 Sun Pharmaceutical Industries, Inc. Deuterated analogs of D-serine and uses thereof
RU2738873C2 (ru) * 2018-12-29 2020-12-17 Общество С Ограниченной Ответственностью "Сольвекс" (Ооо "Сольвекс") Препарат для магнитно-резонансной томографии, содержащий дейтерированный саркозин, и способ диагностики с использованием этого препарата
US12065395B2 (en) 2019-04-03 2024-08-20 Sun Pharmaceutical Industries, Inc. Processes for the preparation of deuterated D-serine
WO2020243638A1 (en) * 2019-05-30 2020-12-03 Concert Pharmaceuticals, Inc. Methods of treatment with deuterated analogs of d-serine
EP4744678A2 (en) * 2019-12-19 2026-05-20 Intra Cellular Therapies Inc LUMATEPERONE FOR THE TREATMENT OF SCHIZOPHRENIA
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582931A (en) * 1984-12-24 1986-04-15 Merck & Co., Inc. Preparation of 2-Deutero-D-serine
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
JP2000501707A (ja) 1995-12-07 2000-02-15 ジャビット，ダニエル・シー グリシン捕捉性アンタゴニストを用いる拒絶性および認知性精神分裂病症候群の処置
US6361957B1 (en) 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
US5845286A (en) 1996-12-24 1998-12-01 Colizza; Vincent Date value reduction system
US6228875B1 (en) * 1998-04-14 2001-05-08 The General Hospital Corporation Methods for treating neuropsychiatric disorders
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
US6258605B1 (en) 1999-03-26 2001-07-10 Neo Gen Screening, Inc. Clinical method for the genetic screening of newborns using tandem mass spectrometry
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
DK1104760T3 (da) 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
PT1390063E (pt) 2001-05-03 2005-03-31 Hoffmann La Roche Forma de dosagem farmaceutica de mesilato de nelfinavir amorfo
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
IL154318A (en) * 2003-02-06 2010-05-31 Sarah Herzog Memorial Hospital Pharmaceutical compositions for the treatment of movement disorders
US20060094744A1 (en) 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
JP5266042B2 (ja) 2005-04-11 2013-08-21 エール ユニヴァーシティ 統合失調症前駆症の治療方法
US7598273B2 (en) 2005-10-06 2009-10-06 Auspex Pharmaceuticals, Inc Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US20080103122A1 (en) 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
IL188681A0 (en) 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
WO2012019106A2 (en) 2010-08-06 2012-02-09 Board Of Regents Of The University Of Nebraska Positive and negative modulators of nmda receptors
US9040581B1 (en) 2013-02-21 2015-05-26 The Florida State University Research Foundation, Inc. Methods of treatment using D-serine
US9687460B2 (en) 2013-05-28 2017-06-27 Sarah Herzog Memorial Hospital-Ezrath Nashim Autoimmune-induced glutamatergic receptor dysfunction methods and treatments
WO2014205074A2 (en) 2013-06-18 2014-12-24 The Trustees Of Columbia University In The City Of New York Devices, compositions and methods for imaging with raman scattering
WO2015160470A2 (en) * 2014-03-20 2015-10-22 The Trustees Of Princeton University Nadph production by the 10-formyl-thf pathway, and its use in the diagnosis and treatment of disease
GB201521903D0 (en) 2015-12-11 2016-01-27 Electrophoretics Ltd Isorbaric mass labels
DK3465202T3 (da) 2016-06-02 2023-08-21 Metabolon Inc Massespektrometrifremgangsmåde til detektering og kvantitering af metabolitter
AU2018371784B2 (en) 2017-11-22 2024-10-17 Sun Pharmaceutical Industries, Inc. Deuterated analogs of D-serine and uses thereof
US20220313640A1 (en) 2019-05-29 2022-10-06 Dario Doller Deuterated analogs of d-serine and uses thereof

Also Published As

Publication number Publication date
AU2025200345A1 (en) 2025-02-13
BR112020010156A2 (pt) 2020-11-10
JP2021504326A (ja) 2021-02-15
IL274585A (en) 2020-06-30
JP2023123476A (ja) 2023-09-05
EP4560024A3 (en) 2025-08-20
JP7518765B2 (ja) 2024-07-18
KR20200103662A (ko) 2020-09-02
US12029712B2 (en) 2024-07-09
US10668036B2 (en) 2020-06-02
WO2019104179A4 (en) 2019-08-01
US20250000830A1 (en) 2025-01-02
KR102916897B1 (ko) 2026-01-26
CA3082834A1 (en) 2019-05-31
IL274585B2 (en) 2026-01-01
IL274585B1 (en) 2025-09-01
US20200368193A1 (en) 2020-11-26
CN111491629A (zh) 2020-08-04
TW201924668A (zh) 2019-07-01
AU2018371784B2 (en) 2024-10-17
MX2020005336A (es) 2020-08-13
JP2025138735A (ja) 2025-09-25
TWI886093B (zh) 2025-06-11
EP3713557B1 (en) 2025-03-12
EP3713557A1 (en) 2020-09-30
US20190328692A1 (en) 2019-10-31
AU2018371784A1 (en) 2020-05-28
US20200390732A1 (en) 2020-12-17
JP7733058B2 (ja) 2025-09-02
WO2019104179A1 (en) 2019-05-31
IL322463A (en) 2025-09-01
EP4560024A2 (en) 2025-05-28

Similar Documents

Publication Publication Date Title
IL293377A (en) Hsd17b13 variants and uses thereof
PL3727426T3 (pl) Analogi inkretyny i ich zastosowania
PL3383916T3 (pl) Przeciwciała anty-cd73 i ich zastosowania
PL3630917T3 (pl) Równomiernie zamknięte nanocząstki i ich zastosowania
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
PL3280441T3 (pl) Przeciwciała przeciwko sortilinie i sposoby ich stosowania
PL3359563T3 (pl) Receptory antygenów i ich zastosowania
EP3568600A4 (en) CLAMP
DK3347006T3 (da) Deutererede analoger af etifoxin, derivater deraf og anvendelser deraf
SI3672948T1 (sl) Piridinamin-piridon in spojine pirimidinamin-piridona
IL274585A (en) Deuterated D-serine analogs and uses thereof
PL3337506T3 (pl) Kombinacje i ich zastosowania
EP3717554A4 (en) EXPANDABLE ACRYLIC COMPOSITION
EP3546581A4 (en) MICRO-ORGANISMECORYNEBACTERIUM
MA49905A (fr) Polyesteramines et polyesterquats
PT4077317T (pt) Tieniloxazolonas e análogos
PL3386916T3 (pl) Ulepszenia w wytwarzaniu nanocząstek krzemu i ich zastosowania
HUE057833T2 (hu) Öv kitüremkedésekkel
EP3617548A4 (en) TIMING BELT
IT201700039351A1 (it) Miscela antimeristematica e antigermogliante
IL284201A (en) Forms and histories of deuterium valencerin
EP3680281A4 (en) Acrylic film
IT201700046708A1 (it) Cintura
UY4593S (es) Guillermina curva y balerina curva
EP3724329C0 (en) AMINOPEPTIDASE AND ITS USES